Clinical Trials Browser

Myeloproliferative Disorders × selinexor × 90 days × Clear all

NCT07626021 2026-06-04

Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms

Phase 2 Not yet recruiting

Myeloproliferative Disorders

NCT04562389 2026-04-09

SENTRY

Phase 3 Active not recruiting

Myeloproliferative Disorders, Primary Myelofibrosis